Drug Policy Watch · State Brief 2026

District of Columbia

Snapshot (structured)

Adult-use cannabis: Possession and home cultivation legal for adults 21+ under Initiative 71 (since Feb 2015), but commercial taxed retail sales remain blocked by the congressional Harris rider. No legal storefront adult-use market exists.
Medical cannabis: Legal and operating. Adults 21+ can self-certify (no doctor recommendation needed) and buy immediately on applying online. Program serves roughly 29,000 unique DC resident patients plus non-residents.
Home grow: Legal under Initiative 71. Up to 6 plants per person (no more than 3 mature), max 12 per household.
Intoxicating hemp / hemp THC: Delta-8 THC and similar intoxicating cannabinoids are treated as controlled substances in DC; exposure to the new federal hemp redefinition (H.R. 5371, signed Nov 12 2025) with most intoxicating hemp restrictions taking effect Nov 12 2026.
Psychedelics: Initiative 81 (2021) makes enforcement of laws against entheogenic plants and fungi among the lowest police priorities. No legal sales, no state-run therapeutic program.
Broad decriminalization: Marijuana possession legal; no broad decriminalization of other drugs. Possession of other controlled substances remains illegal.
Harm reduction: Syringe services, free naloxone/Narcan, fentanyl test strips distributed via LIVE.LONG.DC. No authorized safe consumption sites.
Mayor (party): Muriel Bowser (Democrat).
Council control: Democratic-controlled; Chairman Phil Mendelson (Democrat).
Citizen ballot initiatives allowed: Yes (5% of registered voters signatures required, roughly 24,836 in recent cycles).
Enclosure pressure score: 3/5

Cannabis

Initiative 71, approved by about 64.9% of DC voters on November 4 2014 and in full effect since February 26 2015, legalized possession of up to two ounces, home cultivation of up to six plants (three mature) per person, and gifting of up to one ounce between adults 21+. Crucially it did not, and legally could not, set up taxed commercial sales (https://ballotpedia.org/Washington_D.C.Marijuana_Legalization,_Initiative_71(November_2014); https://en.wikipedia.org/wiki/2014_Washington,_D.C.,_Initiative_71).

The congressional rider. Since fiscal 2015, Rep. Andy Harris (R-MD) has attached a rider to every federal appropriations bill barring DC from spending local funds to establish a regulated, taxed adult-use commercial market. As of late 2025, the Harris rider survived again in appropriations, leaving adult-use retail licensing on indefinite hold. Reporting in 2025 noted a narrow opening discussion around the rider, but commercial adult-use sales remain blocked into 2026 (https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/dc-2025-harris-rider-gifting-enforcement-outlook; https://www.wusa9.com/article/news/local/marijuana-commercial-sales-dc-harris-rider-appropriations/65-c942fe27-9e7e-4b2c-9b72-47ada86f9f42; https://www.mpp.org/states/district-of-columbia/).

The gifting market and its crackdown. Because retail sales were blocked, a large "gifting" gray market emerged, where shops sold a sticker, t-shirt, or token item and "gifted" cannabis with the purchase. Estimates put unlicensed storefronts at well over 200 at peak. DC moved to convert these into the medical market and to shut down holdouts. A key grace period expired March 31 2025; after that, ABCA and the Metropolitan Police Department (MPD) escalated padlock raids. As of April 1 2025, 41 unlicensed stores transitioned into the legal medical market, a little under half of unlicensed applicants and well under a quarter of total estimated storefronts (https://gwhatchet.com/2025/04/21/local-cannabis-gifting-shops-transition-to-medical-marijuana-after-dc-overhauls-market/; https://outlawreport.com/under-a-quarter-of-d-c-unlicensed-cannabis-shops-transition-to-the-legal-market/; https://washingtondccannabis.org/news-27feb2025). Mayor Bowser announced the 100th illegal cannabis business closure since enforcement began in September 2024 (https://abca.dc.gov/release/mayor-bowser-announces-100th-illegal-cannabis-business-closure-emergency-amendment-act-202-0). Enforcement continued into 2026: ABCA and MPD reported shutting Treehouse DC, Pressure Deliveries, and Level Up Smoke and Tobacco Shop in late March 2026 for illegal cannabis sales posing an imminent danger to public health and safety (https://abca.dc.gov/release/abca-and-mpd-shut-down-illegal-cannabis-operations-across-district). Investigators have reported product seized in raids testing positive for other substances including amphetamines and psilocybin (https://oag.dc.gov/release/attorney-general-schwalb-shuts-down-illegal).

The medical program and emergency amendments. DC's medical program is robust and has been used as the legal channel for the gray market. Under self-certification (originally the Medical Marijuana Self-Certification Emergency Amendment Act of 2022, signed by Mayor Bowser July 6 2022), DC residents 21+ can certify their own qualifying need without a healthcare provider recommendation and purchase immediately upon applying online (https://abca.dc.gov/release/eligible-dc-residents-can-now-purchase-medical-cannabis-immediately-upon-applying-online; https://content.govdelivery.com/accounts/DCWASH/bulletins/31f47fe). Effective March 2 2025 new patient registrations issue for two-year periods; effective July 17 2025 temporary patient and caregiver registrations were extended from 30 to 90 days amid an application surge (https://outlawreport.com/d-c-cannabis-regulators-extend-temporary-patient-cards-amid-surge-in-applications/). The program serves roughly 29,000 unique DC resident patients plus thousands of non-residents (https://en.wikipedia.org/wiki/District_of_Columbia_Alcoholic_Beverage_and_Cannabis_Administration).

Key 2026 actions. The Medical Cannabis Conditional Licensure Extension legislation extended conditional licenses from two to three years; the temporary version passed January 23 2026 (Law L26-0071, effective from Dec 31 2025, retroactive to June 28 2025) to protect small and equity owned businesses that struggled to open due to real estate and funding obstacles (https://themarijuanaherald.com/2025/10/d-c-extending-medical-cannabis/; https://outlawreport.com/d-c-council-passes-bill-extending-conditional-cannabis-licenses/). On April 2 2026, Chairman Mendelson, at Mayor Bowser's request, introduced the Medical Cannabis Beverage Product Amendment Act of 2026, allowing alcohol manufacturers (class A or B license holders) to obtain a $500/year endorsement to produce alcohol-free medical cannabis beverages for sale only at licensed dispensaries to registered patients, with a 6% sales tax and required local lab testing; medical manufacturers could pay a $1,000/year endorsement to import cannabinoids (https://www.marijuanamoment.net/dc-mayor-proposes-to-let-medical-marijuana-and-alcohol-companies-partner-on-thc-drinks; https://mayor.dc.gov/release/mayor-bowser-announces-legislation-diversify-medical-cannabis-market-local-beverage; https://www.cannabisbusinesstimes.com/us-states/dc/news/15821451/washington-mayor-suggests-alcohol-cannabis-companies-partner-on-thc-beverages).

Hemp

DC's controlled substances list names delta-8 THC specifically and DC has no broad "hemp" exemption that would shield intoxicating hemp cannabinoids, so delta-8 and similar converted cannabinoids are treated as controlled substances locally (https://cbdoracle.com/news/policy/washington-dc-delta-8-thc-laws/). Federally, the appropriations and shutdown package (H.R. 5371) signed November 12 2025 narrowed the federal definition of "hemp" to exclude lab-made or converted cannabinoids and capped total THC, effectively banning most intoxicating hemp products; the major restrictions take effect November 12 2026 (a one-year transition) (https://www.regulatoryoversight.com/2025/12/congress-narrows-federal-definition-of-hemp-effectively-banning-most-intoxicating-hemp-products/; https://www.saul.com/insights/alert/congress-enacts-hemp-thc-products-ban-what-new-federal-restrictions-mean-industry; https://perkinscoie.com/insights/update/shutdown-legislation-brings-new-hemp-rules). Recent DC-specific Council action: I did not find a confirmed standalone 2026 DC Council intoxicating-hemp bill; status of any local DC hemp bill is unconfirmed pending the DC Council legislative tracker (https://lims.dccouncil.gov/). Because intoxicating hemp was already largely controlled in DC, the practical local effect of the federal change is smaller than in states that allowed an open hemp THC market.

Psychedelics

Initiative 81, the Entheogenic Plant and Fungus Policy Act of 2020, was approved by DC voters in November 2020 and took effect in 2021 after the congressional review period. It makes enforcement of laws against the non-commercial use, possession, and cultivation of entheogenic plants and fungi (including psilocybin mushrooms, ayahuasca, iboga, and mescaline-containing cacti) among the lowest law enforcement priorities for MPD (https://psychedelicalpha.com/news/dcs-initiative-81-becomes-law-effectively-decriminalizes-entheogenic-plants-and-fungi; https://ballotpedia.org/Washington,D.C.,_Initiative_81,_Entheogenic_Plants_and_Fungus_Measure(2020); https://en.wikipedia.org/wiki/Initiative_81). Important limits: Initiative 81 does not legalize entheogens, does not reduce statutory penalties, and does not authorize for-profit sales; it is a deprioritization measure, not legalization or a therapeutic-access program. There is no DC-regulated psilocybin therapy program comparable to Oregon or Colorado. 2026 measures: I found no confirmed 2026 DC therapeutic-access psychedelics bill; status unconfirmed (https://lims.dccouncil.gov/).

Broader drug policy

Decriminalization. Beyond marijuana (legal under Initiative 71) and the entheogen deprioritization under Initiative 81, DC has not broadly decriminalized possession of other controlled substances; possession of substances such as fentanyl, cocaine, and heroin remains illegal.

Harm reduction. DC operates syringe services programs, distributes free naloxone (Narcan, available over the counter since 2023) and fentanyl test strips, and offers free online naloxone training, coordinated through the LIVE.LONG.DC opioid strategy (https://livelong.dc.gov/page/resources-LLDC; https://livelong.dc.gov/page/about-live-long-dc). Safe consumption sites: LIVE.LONG.DC has long included exploring the feasibility of safe consumption/safe injection sites (a strategy in the plan), but DC has not opened authorized sites; a 2025 federal executive order warned against funding "harm reduction" or "safe consumption" efforts, and at-large Councilmember Janeese Lewis George has voiced support for such sites (https://livelong.dc.gov/page/livelongdc-30; https://www.washingtonexaminer.com/news/campaigns/4584819/janeese-lewis-george-backs-safe-drug-injection-site-dc/). Their authorization status is unconfirmed but they are not operating.

Sentencing and expungement. The Second Chance Amendment Act of 2022 (D.C. Law 24-284) cleared congressional review March 16 2023 but took effect March 1 2025 after funding was approved. It provides automatic expungement of records for simple marijuana possession of any quantity before February 15 2015, automatic sealing for non-convictions and most misdemeanors after waiting periods, and petition-based relief for most other records; courts have until October 2027 to clear old records, with new qualifying records expunged within 90 days of case termination (https://ccresourcecenter.org/state-restoration-profiles/district-of-columbia-restoration-of-rights-pardon-expungement-sealing/; https://www.zuckerman.com/blog/understanding-the-second-chance-amendment-act-a-guide-for-d-c-practitioners-on-expungement-and-record-sealing/; https://norml.org/blog/2023/03/15/district-of-columbia-marijuana-expungement-bill-enacted-into-law/).

Overdose and treatment policy. DC overdose deaths fell sharply from 648 in 2023 to about 406 in 2024 (a drop of more than 37%), with fatal opioid overdoses falling from 516 to 342, attributed in part to wider naloxone availability (https://www.axios.com/local/washington-dc/2025/05/20/overdose-deaths-decline-narcan). Note: one later report cites a 2025 figure of 232 fatal overdoses and 6,117 non-fatal overdoses; the precise 2025 fatal total and trend direction are unconfirmed and figures across sources do not cleanly reconcile, so treat 2025 numbers as preliminary (https://www.ajmc.com/view/drug-overdoses-drop-by-14-in-2025-compared-with-previous-year).

Political landscape

Mayor: Muriel Bowser (Democrat). DC Council: Democratic-controlled, led by Chairman Phil Mendelson (Democrat). Cannabis policy is largely driven jointly by the Bowser administration and Mendelson, who has repeatedly carried cannabis legislation at the mayor's request, including license extensions, the beverage bill, and emergency enforcement measures (https://chairmanmendelson.com/category/news/; https://www.marijuanamoment.net/dc-mayor-proposes-to-let-medical-marijuana-and-alcohol-companies-partner-on-thc-drinks). Attorney General Brian Schwalb has led enforcement publicity against unlicensed shops (https://oag.dc.gov/release/attorney-general-schwalb-shuts-down-illegal). The relevant Council committee oversight (ABCA falls under the committee handling business/regulatory affairs) is not independently confirmed here and the specific 2026 committee assignment is unconfirmed. Mendelson has argued multistate operators (MSOs) help finance the illegal gifting market, a notable opponent framing of the gray market (https://outlawreport.com/mendelson-says-msos-are-financing-d-c-s-illegal-cannabis-gifting-market/). Reform champions and named opponents beyond the above are not cleanly confirmed; named individuals are limited to those above to avoid invention. The defining external constraint is Congress: through the Harris rider, federal lawmakers (not DC) block the commercial adult-use market, the single most important fact about DC cannabis policy (https://www.mpp.org/states/district-of-columbia/).

Ballot initiatives

DC permits citizen initiatives and Council-referred measures. A citizen initiative needs signatures equal to 5% of registered voters (roughly 24,836 in recent cycles, with additional ward distribution requirements). DC initiatives are numbered sequentially over time (Initiative 71, 77, 81, 82, 83, etc.) (https://ballotpedia.org/Local_ballot_measures,Washington,_D.C.; https://dcist.com/story/18/06/19/hey-dc-election-nerds/). Initiative 71 (2014) legalized possession and home grow with about 64.9% support and took effect February 26 2015; it could not legalize sales, which is why the gifting market arose (https://ballotpedia.org/Washington_D.C._Marijuana_Legalization,_Initiative_71(November_2014)). Initiative 81 (2020) deprioritized entheogen enforcement; Decriminalize Nature DC filed 36,249 signatures (https://ballotpedia.org/Washington,D.C.,_Initiative_81,_Entheogenic_Plants_and_Fungus_Measure(2020)). Any pending drug-policy ballot measure for 2026: none confirmed; status unconfirmed.

Equity and expungement

Social equity is built into the medical market: 50% of all new medical cannabis business licenses (except testing labs) are reserved for social equity applicants, and approved social equity applicants get a 75% fee reduction for the first three years. A standard retailer license fee is about $16,000/year ($4,000 for social equity for the first three years); cultivation center application fee is about $8,000 standard versus $800 conditional/social equity (https://abca.dc.gov/page/medical-cannabis-social-equity-applicants; https://indicaonline.com/blog/how-to-get-a-dispensary-license-in-washington-dc/). The 2025-2026 conditional license extension (to three years) was framed specifically to help equity owned businesses that could not open in time due to real estate and capital barriers (https://outlawreport.com/d-c-council-passes-bill-extending-conditional-cannabis-licenses/). On records: the Second Chance Amendment Act provides automatic expungement for pre-Feb-2015 simple marijuana possession and automatic sealing for many other records, benefiting people with old marijuana convictions, though full processing runs through October 2027 (https://norml.org/blog/2023/03/15/district-of-columbia-marijuana-expungement-bill-enacted-into-law/). Who is excluded: those who could not secure capital or compliant real estate within license windows risk losing conditional licenses despite extensions, and the absence of a legal adult-use retail market caps the size of the equity opportunity.

Market and barriers

Hard numbers (where available): roughly 7 licensed medical cannabis retailers operating as of 2025, with about 41 former gifting shops transitioned into the medical market by April 1 2025 (under half of unlicensed applicants, well under a quarter of an estimated 200-plus storefront universe) (https://outlawreport.com/under-a-quarter-of-d-c-unlicensed-cannabis-shops-transition-to-the-legal-market/; https://washingtondccannabis.org/business). Patient base is roughly 29,000 DC residents plus non-residents. Fees: standard retailer about $16,000/year (social equity $4,000); cultivation application about $8,000 (conditional $800); beverage endorsements proposed at $500/year (production) and $1,000/year (import). Taxes: proposed 6% on medical cannabis beverages. As of August 2025 no application period was open for cultivation, manufacturer, or courier licenses (testing labs rolling). The exact current total count of all licensee types (cultivators, manufacturers, couriers) is unconfirmed (https://abca.dc.gov/page/medical-cannabis-business-licenses). Barriers: the Harris rider (no taxed retail), real estate and capital constraints, and the conversion bottleneck from gifting to medical.

Enclosure read

DC is a paradoxical case. Citizens voted twice for the most permissive home-grow-and-gift framework in the country, yet a single member of Congress, through the Harris rider, fences off the one thing that would create an open, taxed local market: legal commercial sales. The result is that the District's own enforcement apparatus (ABCA, MPD, the AG) is now padlocking the gray-market gifting shops that filled the vacuum the rider created, while the only legal commercial channel is the narrow, licensed medical program. Consolidation is real but bounded: a small number of licensed medical retailers (about 7) plus roughly 41 converted shops capture the legal demand, with equity provisions (50% set-aside, fee cuts, license extensions) deliberately softening capture. The proposed beverage bill would route value to existing alcohol manufacturers and licensed medical operators, another mild consolidation lane. Who is fenced out: home growers stay legal but cannot sell; gifting operators who could not convert are being shut down; equity applicants are protected on paper but squeezed by capital and real estate. Justification for 3/5: home grow and possession are genuinely open and equity rules are unusually strong (pulling the score down), but the federally imposed ban on a taxed retail market plus active padlocking of the informal economy and a tiny licensed retail footprint push it up. The unusual feature is that the primary fence is federal control over a non-state, not in-state corporate capture, which is why this is not a 4 or 5.

What to watch next

Federal appropriations timing: whether the Harris rider is renewed or dropped in the next federal spending cycle is the single biggest variable for a DC adult-use commercial market (https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/dc-2025-harris-rider-gifting-enforcement-outlook).
November 12 2026: federal intoxicating-hemp restrictions take full effect after the one-year transition under H.R. 5371 (https://www.saul.com/insights/alert/congress-enacts-hemp-thc-products-ban-what-new-federal-restrictions-mean-industry).
Medical Cannabis Beverage Product Amendment Act of 2026: Council hearings/votes after April 2 2026 introduction (https://mayor.dc.gov/release/mayor-bowser-announces-legislation-diversify-medical-cannabis-market-local-beverage).
Conditional license deadlines: three-year extension (Law L26-0071) buys time but watch new expiration dates for equity operators.
Continued ABCA/MPD enforcement against remaining unlicensed shops through 2026.
Second Chance Act expungement processing deadline of October 2027.

Regulators

Alcoholic Beverage and Cannabis Administration (ABCA): primary regulator for both medical cannabis and alcohol; an independent adjudicatory body, Director Fred Moosally (https://en.wikipedia.org/wiki/District_of_Columbia_Alcoholic_Beverage_and_Cannabis_Administration; https://abca.dc.gov/page/medical-cannabis-program).
Metropolitan Police Department (MPD): joint enforcement against unlicensed cannabis operations.
Office of the Attorney General (OAG): enforcement and shutdown actions (https://oag.dc.gov/release/attorney-general-schwalb-shuts-down-illegal).
Department of Licensing and Consumer Protection (DLCP): participates in joint enforcement and product testing operations.
DC Health / Department of Behavioral Health (DBH): overdose prevention and treatment via LIVE.LONG.DC (https://livelong.dc.gov/).
US Congress: controls DC's budget and, via the Harris rider, blocks the commercial adult-use market.

Federal exposure (2026)

DC is the most federally determined drug-policy jurisdiction in the country. As a federal district rather than a state, it has no sovereign buffer: Congress controls the DC budget and can, and does, dictate local drug policy directly. The levers below are not background conditions for DC, they are the operative law.

The congressional Harris rider (the defining fence). Since fiscal 2015, the appropriations rider associated with Rep. Andy Harris (R-MD) has barred DC from spending local funds to stand up a regulated, taxed adult-use commercial market. This is unique among legal-cannabis jurisdictions: DC voters legalized possession and home grow through Initiative 71, but a single member of the federal legislature blocks the retail market that every other adult-use jurisdiction has built. The rider survived the late-2025 appropriations cycle and remains in force into 2026, so the only legal commercial storefront channel is the licensed medical program. No state-level political actor can lift this fence; only Congress can, which is why federal appropriations timing is the single biggest variable for DC (https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/dc-2025-harris-rider-gifting-enforcement-outlook; https://www.mpp.org/states/district-of-columbia/).

Rescheduling and 280E. On April 22, 2026, Acting Attorney General Todd Blanche signed a final DOJ/DEA order moving FDA-approved cannabis drugs and state-licensed MEDICAL cannabis from Schedule I to Schedule III, effective immediately; recreational cannabis stays Schedule I (https://www.saul.com/insights/alert/dea-reschedules-fda-approved-marijuana-products-and-state-licensed-medical-marijuana; https://www.congress.gov/crs-product/LSB11424). For DC this matters specifically because the medical program is the District's only legal commercial channel. DC's licensed medical operators fall within the rescheduled medical category and therefore gain relief from IRC Section 280E, which had barred normal business deductions, improving the economics of the one storefront lane DC is allowed to have. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not reach DC's home-grow-and-gift Initiative 71 activity (which is recreational and remains Schedule I federally). A broader DEA hearing on rescheduling all cannabis opened June 29, 2026 and may slip to 2027; until it concludes, the relief is confined to the medical category (https://www.gibsondunn.com/dea-downschedules-state-medical-marijuana-to-schedule-iii-expedited-hearing-set-to-consider-broader-rescheduling/).

The November 12, 2026 hemp cliff. DC already controls delta-8 THC and similar converted cannabinoids locally, so the District never ran the open intoxicating-hemp market that the new federal total-THC standard is designed to shut down. The FY2026 agriculture appropriations provision (Sec. 781, associated with Rep. Andy Harris R-MD) narrows hemp to a total-THC standard (about 0.4 mg THC per container), recriminalizing roughly 90 to 95 percent of intoxicating hemp products effective November 12, 2026; the H.R. 7010 delay was not enacted and the 2026 Farm Bill (H.R. 7567) keeps the ban (federal sponsors of H.R. 7010 and H.R. 7567 not individually confirmed here, unconfirmed: https://www.congress.gov/). The federal ban interacts with DC's existing local controls by reinforcing them: where DC already treated these cannabinoids as controlled, the federal change closes any residual interstate or gray-channel supply, so the practical local shock is smaller than in states that had permitted an open hemp THC market (https://www.saul.com/insights/alert/congress-enacts-hemp-thc-products-ban-what-new-federal-restrictions-mean-industry).

Banking. The SAFER Banking Act remains stalled in Congress, so DC's licensed medical operators continue to face limited access to mainstream banking, card processing, and lending. The April 2026 Schedule III move for medical cannabis improves tax treatment but does not by itself resolve the banking gap, which still depends on federal legislation that has not advanced.

Psychedelics. Initiative 81 (2020) makes enforcement of laws against entheogenic plants and fungi among the lowest priorities for MPD, but it does not legalize them and creates no legal market or therapeutic-access channel. Federally, psilocybin, MDMA, and ibogaine remain Schedule I. An April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review of psychedelic therapies, but there is no federal approval yet. So DC's lowest-enforcement-priority posture sits underneath an unchanged federal Schedule I ban and a still-pending FDA pathway: deprioritization at the local level, prohibition at the federal level, with no legal supply on either side (https://psychedelicalpha.com/news/dcs-initiative-81-becomes-law-effectively-decriminalizes-entheogenic-plants-and-fungi).

Harm reduction. DC's harm-reduction infrastructure is well developed, with syringe services, free naloxone, fentanyl test strips, and online naloxone training coordinated through LIVE.LONG.DC. That makes DC unusually exposed to the SAMHSA guidance of April 24, 2026, which bars federal funds from being used for fentanyl test strips, clean syringes, and sterile water (and test strips for xylazine and medetomidine), while continuing to support naloxone, sharps disposal, and infectious-disease testing. Because DC's programs lean on federal grant streams and the strips-and-syringes services are exactly what the guidance defunds, the District faces a direct funding hit to components of a program it has invested in, even as naloxone distribution (credited with the sharp 2024 overdose-death decline) stays fundable (https://www.statnews.com/2026/04/27/trump-administration-samhsa-clear-shift-from-harm-reduction/; https://www.naco.org/news/samhsa-implements-new-harm-reduction-restrictions-updated-guidance; https://livelong.dc.gov/page/about-live-long-dc).

Direct congressional control. The structural point underlying all of the above: as a federal district, DC is uniquely subject to direct congressional control of its drug policy. Congress reviews every DC law, controls the DC budget, and through the Harris rider affirmatively blocks a market DC voters chose. No US state operates under this constraint. In DC the federal levers are not merely a ceiling on local choices, they are in places a substitute for them.

Patient access and rights

This section covers what District of Columbia law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): the District of Columbia has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; the District of Columbia is not among them. The absence is the finding: a the District of Columbia patient has no enforceable right to use their medicine in a hospital today.

Broader protections: the District protects a patient in one of the six areas, employment. D.C. Code Section 32-951.02 bars an employer from taking action against an employee based on their status as a qualifying patient or a positive test, subject to limited exceptions. A review of the medical cannabis chapter found no protection for housing, parenting, an organ transplant list, school enrollment, or general medical care. Those gaps are the finding.

Out-of-state patients: the District recognizes out-of-state medical cards, and adults 21 and over may self-certify to use the program.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only local law can force hospital access, and the District has not enacted a Ryan's Law. The broader protections above are a creature of District of Columbia law, not federal law.

Sources: District of Columbia patient protections, D.C. Code Section 32-951.02.

Analysis: the enclosure read in depth

Who is fenced out, and by whom. DC is the unusual case where the fence is federal preemption rather than in-state corporate capture. In a typical state with a high enclosure score, the question is which large incumbents captured the licensed market and squeezed out small and equity actors. In DC the prior question never resolves: the commercial market itself is blocked from existing by the congressional Harris rider. The people fenced out are first and foremost everyone who would participate in a taxed adult-use market, growers, would-be small retailers, equity entrants, and consumers, all of whom are legal to possess and home grow under Initiative 71 but cannot lawfully buy or sell at retail. Second are the gifting-shop operators: the gray market that filled the rider-created vacuum is being actively dismantled through ABCA and MPD padlock raids, with only a minority of unlicensed shops (about 41) converting into the medical channel and well under a quarter of the estimated storefront universe surviving. The medical program is the only legal commercial channel, and it is narrow by design (self-certification widens patient access, but the licensed operator footprint is small, about 7 retailers).

State-plus-federal interaction: federal control IS the enclosure. In most briefs the enclosure read weighs a state framework against federal overlay. In DC the two collapse into one: the federal government is the proximate cause of the closure. The Harris rider blocks the market; the April 2026 Schedule III order hands 280E relief specifically to the medical operators who form the only legal lane, mildly strengthening the incumbents the rider leaves standing; the November 12, 2026 hemp cliff reinforces DC's pre-existing local controls; the SAMHSA cuts defund parts of DC's harm-reduction program; and stalled SAFER Banking keeps even the legal medical operators capital-constrained. Each federal lever lands more directly on DC than on any state because Congress governs the District. The local enclosure dynamics that do exist, the beverage bill routing value to existing alcohol manufacturers and licensed medical operators, the conversion bottleneck favoring those with capital and compliant real estate, are real but secondary to the federal fence.

What to watch. Appropriations timing is the master variable: whether the Harris rider is renewed, narrowed, or dropped in the next federal spending cycle determines whether DC ever gets a taxed adult-use market. Watch also the June 29, 2026 DEA hearing (broader rescheduling could extend 280E relief and Schedule III treatment beyond the medical category, though not legalize recreational), the November 12, 2026 hemp deadline, and whether Congress moves SAFER Banking or revisits the SAMHSA harm-reduction restrictions.

Where commons counter-moves survive. Despite the federal fence, DC retains unusually live bottom-up channels. Home grow and possession under Initiative 71 remain genuinely open: adults 21+ can grow up to 6 plants (3 mature) and possess up to two ounces, a non-commercial commons the rider cannot touch because it requires no DC spending to administer. Initiative 81 keeps entheogen enforcement at the lowest priority, preserving a tolerated non-commercial space. And the DC initiative process itself (5% of registered voters, roughly 24,836 signatures) is the mechanism that produced both 71 and 81 and remains available for further bottom-up policy even while Congress blocks the commercial buildout. These are the counter-moves that survive: personal cultivation, deprioritized entheogen use, and direct democracy, none of which depend on a licensed market.

Justifying the enclosure score (3/5), driven by federal preemption not local capture. The score sits in the middle because two forces pull in opposite directions. Pulling it down: home grow and possession are genuinely open, equity rules in the medical program are unusually strong (50% license set-aside, fee reductions, conditional-license extensions), and the live initiative process keeps a real commons channel open. Pulling it up: a federally imposed ban on the taxed retail market, active padlocking of the informal economy that the ban created, a tiny licensed retail footprint, and a stack of 2026 federal levers (Schedule III favoring incumbent medical operators, the hemp cliff, SAMHSA harm-reduction defunding, stalled banking) that tighten the screws. The decisive and unusual feature is that the primary fence is federal control over a non-state, not in-state corporate capture. That is why DC is a 3 and not a 4 or 5: the enclosure is severe but externally imposed and reversible by a single change in federal appropriations, and the underlying local commons (home grow, deprioritized entheogens, the initiative right) remains intact beneath it.

Active legislation (2026)

This list is not exhaustive. For the full long tail of active measures, see the DC Council Legislative Information Management System tracker: https://lims.dccouncil.gov/. Bill numbers shown are as reported; where a number could not be independently confirmed it is marked unconfirmed.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

Law L26-0071 (temporary act) Medical Cannabis Conditional Licensure Extension Temporary Amendment Act of 2025 (extends conditional licenses 2 to 3 years) (Passed Jan 23 2026; effective from Dec 31 2025, retroactive to June 28 2025)
Medical Cannabis Beverage Product Amendment Act of 2026 (bill number unconfirmed) Lets alcohol manufacturers produce alcohol-free medical cannabis beverages for dispensary sale; import endorsement for cannabinoids (Introduced Apr 2 2026; pending)
Emergency anti-illegal-cannabis bill (bill number unconfirmed) Expands ABCA authority to take summary action and padlock businesses engaged in illegal cannabis commerce (Introduced 2026 (emergency); status pending/unconfirmed)
Harris rider (federal appropriations) Bars DC from spending local funds to establish taxed adult-use commercial cannabis market (Retained in late-2025 appropriations; in effect into 2026)
H.R. 5371 (federal) Narrows federal hemp definition, restricts most intoxicating hemp products (Signed Nov 12 2025; main restrictions effective Nov 12 2026)

Measure	Title/Topic	Body	Status	Sponsor(s)
Law L26-0071 (temporary act)	Medical Cannabis Conditional Licensure Extension Temporary Amendment Act of 2025 (extends conditional licenses 2 to 3 years)	DC Council	Passed Jan 23 2026; effective from Dec 31 2025, retroactive to June 28 2025	Chairman Phil Mendelson, at request of Mayor Bowser
Medical Cannabis Beverage Product Amendment Act of 2026 (bill number unconfirmed)	Lets alcohol manufacturers produce alcohol-free medical cannabis beverages for dispensary sale; import endorsement for cannabinoids	DC Council	Introduced Apr 2 2026; pending	Chairman Phil Mendelson, at request of Mayor Bowser
Emergency anti-illegal-cannabis bill (bill number unconfirmed)	Expands ABCA authority to take summary action and padlock businesses engaged in illegal cannabis commerce	DC Council	Introduced 2026 (emergency); status pending/unconfirmed	Chairman Phil Mendelson, at request of Mayor Bowser
Harris rider (federal appropriations)	Bars DC from spending local funds to establish taxed adult-use commercial cannabis market	US Congress (appropriations)	Retained in late-2025 appropriations; in effect into 2026	Rep. Andy Harris (R-MD)
H.R. 5371 (federal)	Narrows federal hemp definition, restricts most intoxicating hemp products	US Congress	Signed Nov 12 2025; main restrictions effective Nov 12 2026	Federal (sponsor not individually confirmed here)

Several DC bills (B26-0299, B26-0345, B26-0346, B26-0654) surfaced in search as 26th Council cannabis-related measures but their exact titles, current status, and sponsors were not independently confirmed; treat as unconfirmed and verify on the tracker (https://lims.dccouncil.gov/; https://legiscan.com/DC).

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →